Former Blueprint vets take their new biotech out of stealth, with STAT3 in their sights

Recludix Pharma, a San Diego biotech launched by a founding team of Blueprint Medicines vets, pulled in a $60 million Series A on Monday, promising investors a path to the holy grail STAT3 mutation through what’s called the SH2 domain. Taking over as chief executive is Nancy Whiting, arriving after a 15-year run at Seagen that saw her run corporate strategy and late-stage development at various points. Investors in the round included NEA, Westlake Village BioPartners, and Access Industries.